Roche posts strong sales growth in the first nine months of 2013

RocheGroup sales rose 6% to 34.9 billion Swiss francs in the first nine months of the year due to strong demand for Roche's HER2 breast-cancer treatments, as well as higher sales of Avastin and clinical laboratory products from the Diagnostics Division. For the fifth consecutive year Roche was ranked as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry in the Dow Jones Sustainability Index (DJSI), highlighting the Group's commitment to responsible business practices and the creation of long-term value.

Commenting on the Group's first nine months, Roche CEO Severin Schwan said: "Demand for our products has remained strong in both divisions. We will meet our full-year targets. I am very encouraged by the uptake of our new cancer medicines, Perjeta and Kadcyla, which significantly improve the survival rates of patients with a very aggressive form of breast cancer. In diagnostics, we benefited from strong growth in Professional Diagnostics, and the launch of the cobas 8100 will further strengthen our market leadership."

Sales in the Pharmaceuticals Division rose 7% to 27.2 billion Swiss francs as a result of strong demand for Roche's cancer medicines Avastin, Herceptin, MabThera/Rituxan, Perjeta and Kadcyla, as well as rheumatoid arthritis treatment Actemra/RoActemra.

The HER2 breast-cancer franchise, which includes Herceptin, Perjeta and Kadcyla, grew 13% thanks to positive uptake of both Perjeta and Kadcyla following their recent launches. The outlook for the HER2 franchise was further strengthened in September after the European regulatory agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval for Kadcyla in advanced HER2-positive breast cancer. The FDA also granted accelerated approval of Perjeta for the neoadjuvant treatment of HER2-positive breast cancer prior to surgery. Perjeta is the only approved neoadjuvant breast cancer treatment in the United States. In addition, the subcutaneous formulation of Herceptin was approved in Europe, significantly reducing the administration time and related treatment costs of Herceptin.

Avastin sales rose 13% due to recent approvals in ovarian cancer in Europe, colorectal cancer in the United States and Europe, and the first approval for newly diagnosed glioblastoma in Japan.

The division also benefited from a 33% increase in sales for Actemra/RoActemra. Roche is strengthening its immunology/ophthalmology pipeline with the development of new compounds such as etrolizumab for inflammatory bowel disease and lampalizumab (anti-factor D) for geographic atrophy, an advanced form of dry age-related macular degeneration. Etrolizumab is moving into late-stage development, while promising phase II data for lampalizumab were presented at the 31st Annual Meeting of the American Society of Retina Specialists in August.

The United States (+12%) and key emerging markets2 (+10%), in particular China, which grew 23%, were the main regional growth drivers. The United States nine-month net revenue benefited from a sales reserve release in the third quarter amounting to 184 million Swiss francs related to a provision in the US Healthcare Reform3. Sales in Europe rose 2% despite the challenging environment due to demand for specialty care medicines such as Avastin, skin cancer medicine Zelboraf and Actemra.

Roche now has 65 new molecular entities in its pipeline, and around two-thirds of our late-stage compounds are being developed with a companion diagnostic. In September encouraging efficacy and safety data for alectinib, an ALK inhibitor, in patients with advanced non-small cell lung cancer resistant to available treatment were presented at the European cancer congress. The FDA has granted alectinib breakthrough therapy designation.

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012, Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs ($9 billion US) in R&D. The Group posted sales of 45.5 billion Swiss francs ($48.4 billion US). Genentech, United States, is a wholly owned member of the Roche Group. Roche is the majority stake in Chugai Pharmaceutical, Japan.

Most Popular Now

BioNTech's statement on patent infringement lawsui…

BioNTech SE (Nasdaq: BNTX, "BioNTech") published an official statment: "BioNTech is aware of reports that Moderna has sued Pfizer and BioNTech, alleging that COMIRNATY® i...

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...